A DRUG developed by an Australian biotech is showing promise in destroying stubborn brain cancer cells in children and adults.

A PRE-CLINICAL study in the United States has found that the drug, Trilexium (TRXE-009), can destroy brain cancer cells that are resistant to chemotherapy and cause tumours to return.

Originally published asBrain cancer drug shows promise